Paragon recommends capping the exclusion at 125% of the national average value.

As the drugmaker moves into Phase III studies for survodutide, its new GLP-1 obesity drug, Walgreens will use its community pharmacies as clinical trial sites, aiming to improve access and address equitable health representation.

There are many quality improvement and risk mitigation strategies benefit advisors can bring to employers.

Starting a clear path for support to be modeled, enabled and reinforced repeatedly to employees can help remove any perceived stigma they might have.